Anti-Müllerian Hormone and Embryo Aneuploidy
Serum Anti-Müllerian Hormone Levels and Its Association With Aneuploidy Rates in Human Blastocysts
1 other identifier
observational
300
1 country
1
Brief Summary
The goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum Antimullerian hormone (AMH) levels. Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedFirst Submitted
Initial submission to the registry
February 1, 2023
CompletedFirst Posted
Study publicly available on registry
February 10, 2023
CompletedFebruary 10, 2023
February 1, 2023
5 years
February 1, 2023
February 1, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Aneuplody rate
4 years
Secondary Outcomes (2)
Clinical pregnancy rate
4 years
Miscarriage rate
4 years
Study Arms (6)
AMH < 0.5 ng/ml
AMH 0.5-0.99 ng/ml
AMH 1.0-1.49 ng/ml
AMH 1.5-1.99 ng/ml
AMH 2.0-4.99 ng/ml
AMH > 5.0 ng/ml
Interventions
preimplantation genetic test for embryo aneuploidies after IVF
Eligibility Criteria
Patients who underwent a first IVF cycle with PGT-A at the blastocyst stage
You may qualify if:
- All started cycles planned to be followed by preimplantation genetic testing for aneuploidies (PGT-A). PGT-A is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos.
You may not qualify if:
- Data from oocyte donation cycles
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Clinica de la Mujer Medicina Reproductiva
Viña del Mar, Región de Valparaíso, 2520187, Chile
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
February 1, 2023
First Posted
February 10, 2023
Study Start
January 1, 2018
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
February 10, 2023
Record last verified: 2023-02